Fondaparinux

CHEMBL1201202 Phase 4 Onaylandı Oligosaccharide

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1508.3 g/mol

LogP

-14.7

Phase

4

This synthetic anticoagulant inhibits a specific clotting factor called Factor Xa to prevent dangerous blood clots from forming. It is used to prevent and treat deep vein thrombosis and pulmonary embolism, including in patients undergoing orthopedic surgery.

Moleküler Ağırlık

1508,3000 g/mol

LogP

-14,70

TPSA

873,00 Å²

Lipinski RO5

Başarısız

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Non-Small Cell Lung Cancer Deep Vein Thrombosis / Pulmonary Embolism Obesity Breast Cancer Atrial Fibrillation Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O

InChI

InChI=1S/C31H53N3O49S8/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68)/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-/m1/s1

Molecular Formula

C31H53N3O49S8

HBD / HBA

19 / 52

Döndürülebilir Bağlar

30

Ağır Atomlar

91

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This synthetic anticoagulant inhibits a specific clotting factor called Factor Xa to prevent dangerous blood clots from forming. It is used to prevent and treat deep vein thrombosis and pulmonary embolism, including in patients undergoing orthopedic surgery.

Yes, Fondaparinux is an approved drug. It has reached clinical phase 4. It is classified as a Oligosaccharide.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201202. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5282448. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Fondaparinux PillFYI'da

Yapı

Hızlı Veriler

Formül: C31H53N3O49S8
Eş Anlamlılar: 2

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.